![Page 1: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/1.jpg)
![Page 2: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/2.jpg)
2
Our established and differentiated model
Seed and early stage VC investments
Institutional platform to launch innovative ventures
![Page 3: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/3.jpg)
Our Process
3
![Page 4: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/4.jpg)
Our Process
4
Value Proposition Technical Solution
Regulatory Team
Market NeedIP ProtectionVenture
Hypotheses
![Page 5: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/5.jpg)
Our Process
5
![Page 6: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/6.jpg)
Our Process
6
![Page 7: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/7.jpg)
Darwinian process for innovation
7
Exploration Variation
Selection
Proto-company
Venture hypotheses
• Build team
• Establish lab
• Perform PoC experiments
• Develop IP estate
• Secure financing
NewCo
![Page 8: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/8.jpg)
Examples of our VentureLabs companies
8
Pioneer of messenger RNATherapeutics™
Developer of novel oral biologics to transform health
Leading microbiome therapeutics company
Pioneer of microbial solutions to naturally promote
plant health
![Page 9: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/9.jpg)
Messenger RNA Therapeutics for in vivo generation of biological drugs
• Developing novel biotherapeuticmodality, Messenger RNA Therapeutics™ - mRNA administered in vivo to produce many different types of therapeutic proteins
• No use of viral vectors for delivery, no genomic integration, and no use of rDNA for manufacturing
• Dozens of approved and novel protein therapeutics expressed -Non-Human Primate studies underway
• Landmark partnership with AstraZeneca and additional partnerships w/Alexion and Merck
• Raised an unprecedented $450M in private funding then additional $100M investment from Merck
1. Make a specific mRNA messenger therapeutic
2. Administer to patients, resulting in intracellular protein production
3. Therapeutic impact can be local (intracellular) or systemic (secreted)
Daily injection of GEN2 mRNA EPO in mice, serum hEPO levels
moderna technologyEvades innate immunity
Intramuscular injection of mRNA (200 ug) in mice,
serum collected 8 hrs later
Day 4Day 3Day 2Day 1
+-+-+-+-
9
![Page 10: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/10.jpg)
10
Therapeutic microbial ecologies to restore human microbiome health
• Developing a new class of therapeutics to fully restore healthy microbial ecosystems based on a new understanding of the biology of the microbiome to impact human health and cure disease
• Breakthrough approach for monitoring, culturing, and shaping human microbial ecosystems
• Broad therapeutic opportunities with potential for fast clinical path in several indications
• Completed Phase I/II study for SER-109 in recurrent C. difficile resulted in clinical cures, with 29 of the trial's 30 patients (97 percent) reaching the 8-week endpoint free of infection
• Follow-on programs in inflammatory and metabolic indications advancing to clinic
Antibiotics Prebiotics Probiotics
Symbiosis
Ecobiotics
Dysbiosis
![Page 11: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/11.jpg)
Beneficial microbes to naturally promote crop health
• Pioneering microbial solutions to naturally promote plant health and improve agricultural production by harnessing the beneficial microbes that reside within plants
• Substantial platform with multiple products in greenhouse and field trials worldwide in globally-important crops including corn, soy, wheat, cotton, and vegetables
• Senior advisors include renowned experts in agribusiness, the plant microbiome, plant sciences, and computational ecology
• Leading IP portfolio in agriculture
• Germinated from 2012 summer fellows exploration
11
NT Control SYMNT Control SYM
![Page 12: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/12.jpg)
Restore imbalances in amino acids at the heart of important diseases
109 candidatesxxx
x
xx
x Commodity Proteins
• Developing a new class of healthcare products, therapeutic nutrients, intended to treat or prevent major human diseases
• Transforming health by unlocking the potential of homeostatic biology
• Developed a proprietary library with over one billion proteins along with the tools necessary to select, validate and express individual proteins with precise amino acid and biophysical profiles
• Two lead products, one for muscle, and one for pre-diabetes, being developed, with broad platform depth behind
12
![Page 13: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/13.jpg)
VentureLabs Associate• Several explorations
• Nitrogen fixation, natural gas, catalysts, intra-cranial pressure monitoring, the brain, drug screening
• Found & Launch NewCos• Operational roles
13
Before Flagship:• US Fulbright Scholar to India- Biofuels development• MBA/MS Dual degree, Univ. Pittsburgh• Biogen Idec• BS, Northwestern University
- Creative innovation- Invention + Operation- Platform companies with a big vision
2012 2013 2014 2015
Perspective from the Inside: John Round
Summer Fellow
![Page 14: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/14.jpg)
New Associate Profile: Alex Nichols
14
Pre-HST: Early employee at early stage startup (QD Vision, Inc.)
HST (Biophysics), 2014 defense• Oxygen-sensing nanoconjugates for tissue
imaging• 3 patent applications filed on SMART
bandage platform• Started independent consulting company
(Crown Line Consulting, LLC)• Biotechnology• Ski Industry
• Involved in creation of Translational Medicine Fellowship Program at MGH
• VentureLabs Fellow, 2013
Associate, Flagship Ventures, November 2014
![Page 15: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/15.jpg)
VentureLabs Fellows program
15
![Page 16: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/16.jpg)
Fellowship at a Glance
• 6 Fellows programs completed
• 75+ graduates
• Hundreds of ideas explored in life sciences and sustainability
• Numerous breakthrough technologies invented
• Hundreds of US patent applications filed
• Many Fellows now members of the VentureLabs team, leaders at Flagship portfolio companies and successful entrepreneurs
16
![Page 17: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/17.jpg)
Program benefits
• Learn our system of entrepreneuring to generate and refine actionable venture hypotheses
• Contribute to the creation of game-changing ideas & innovations that can be developed into the next breakthrough companies
• Work directly with highly experienced Flagship Venture Labs team members—a group of widely recognized scientists, entrepreneurs and executives
• Build relationships and expand your network with a diverse and highly successful group of peers
• Exhibit and develop your creativity, adaptability, and ability to innovate
• Gain exposure to leaders in science and business providing a highly potent platform for personal growth
• Opportunities to become a member of the VentureLabs team at Flagship or one of our portfolio companies
17
![Page 18: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/18.jpg)
Qualifications
• Deep scientific or business background aimed at life sciences
• Demonstrated entrepreneurial behaviors
• Academic excellence and self-starter mentality: confident, passionate, persuasive
• Creativity in the ability to solve complex scientific and business problems
• Previous Peace Corps, military, or public service experience considered
• Currently a graduate or post graduate student (MBA, MS, PhD, MD, etc.) with a scientific background from a top university
• No more than 1-2 years away from full-time employment
18
![Page 19: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/19.jpg)
Details
• Fellowship runs in two cohorts, each over a 12 week period
• Cohort 1: June 8, 2015 – August 28, 2015
• Cohort 2: Sept. 14, 2015 – Dec. 4, 2015
• Fellows will receive a stipend
• Program takes place at the Flagship VentureLabs offices in Kendall Square: One Memorial Drive, 7th floor, Cambridge
19
![Page 20: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/20.jpg)
How to apply
20
Access [email protected] a CV or resume, including a list of any patents or publications, and indicate which cohort you are interested in. Resumes are reviewed on a rolling basis until all positions are filled. Select applicants will be invited to an in-person interview.
FlagshipVentures.com/VentureLabs/fellows-program
@VLabsFellows
![Page 21: Our established and differentiated model 0311 VLabs_Presentation_MGH.pdfprevent major human diseases •Transforming health by unlocking the potential of homeostatic biology •Developed](https://reader030.vdocument.in/reader030/viewer/2022011822/5ecac74fef9ce743fd743578/html5/thumbnails/21.jpg)
Thank you.
Questions? Comments?